Previous 10 | Next 10 |
2023-09-26 17:35:39 ET More on Aytu BioScience Seeking Alpha’s Quant Rating on Aytu BioScience Historical earnings data for Aytu BioScience Financial information for Aytu BioScience For further details see: Aytu BioScience FQ4 Earnings Preview
2023-09-26 17:35:05 ET Major earnings expected after the bell on Tuesday include: Micron Technology ( MU ) Jefferies Financial Group ( JEF ) Aytu Biopharma ( AYTU ) Concentric Corporation ( CNXC ) For further details see: Notable earnings after Tu...
ENGLEWOOD, CO / ACCESSWIRE / September 21, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report financial results for its fourth quarter and fiscal year ended June 30, 2023, after the market close o...
ENGLEWOOD, CO / ACCESSWIRE / September 13, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that its CEO, Josh Disbrow, and CFO, Mark Oki, will be will be participating in the LD Micro Main ...
Dallas, Texas--(Newsfile Corp. - August 8, 2023) - Stonegate is pleased to announce the release of a thematic report that examines small market cap pharmaceutical companies based on revenue growth and valuation. The report: Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline ex...
2023-07-31 08:37:42 ET China Natural Resources ( NASDAQ: CHNR ) +49% . Allarity Therapeutics ( ALLR ) +31% . Barnes & Noble Education ( BNED ) +17% . Spero Therapeutics ( SPRO ) +13% Announces Special Protocol Assessment Agreement with FDA...
After the completion of local regulatory approvals, Aytu anticipates exporting to Medomie both of its novel, orally disintegrating, extended-release tablets for the treatment of ADHD ENGLEWOOD, CO and GIVATAYIM, ISRAEL / ACCESSWIRE / July 31, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu...
Company Expects a Six-Month Review of the Prior Approval Supplement Submission by the U.S. Food & Drug Administration Which, if Approved, Enables the Transfer of Cotempla Production to Contract Manufacturer Upon Completion of Manufacturing Transfer of Adzenys XR-ODT and Cotempla XR-ODT, ...
ENGLEWOOD, CO / ACCESSWIRE / June 14, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced Joshua Disbrow, Aytu's Chief Executive Officer, will participate in a company discussion...
Abhinav Jain of Nantahala Capital Management, LLC Joins the Company's Board of Directors Upon Closing Potential for Additional $7 Million in Event of Exercise of Common Warrants in Full Extends Interest Only Period on Avenue Capital Term Loan Through January 2025 Maturity Date ENGLE...
News, Short Squeeze, Breakout and More Instantly...
Company receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debt Interest rate on new $13.0 million term loan reduced by approximately 350 basis points today, potentially saving the Company $1.3 million over the life of the term loan T...
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and corporate access firm, today announced the schedule for its Spring 2024 Investor Conference taking place virtually on May 30, 2024. More than 40 companies will be available...
DENVER, CO / ACCESSWIRE / May 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one meetings with inv...